1. Home
  2. FTRE vs IVA Comparison

FTRE vs IVA Comparison

Compare FTRE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

N/A

Current Price

$18.13

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

IVA

Inventiva S.A. American Depository Shares

N/A

Current Price

$4.72

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FTRE
IVA
Founded
1996
2011
Country
United States
France
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
FTRE
IVA
Price
$18.13
$4.72
Analyst Decision
Buy
Strong Buy
Analyst Count
9
10
Target Price
$14.06
$16.20
AVG Volume (30 Days)
1.6M
671.3K
Earning Date
05-05-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,723,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.09
$751.20
P/E Ratio
N/A
N/A
Revenue Growth
1.00
N/A
52 Week Low
$8.31
$3.35
52 Week High
$21.39
$7.98

Technical Indicators

Market Signals
Indicator
FTRE
IVA
Relative Strength Index (RSI) 50.08 57.98
Support Level $16.92 $4.46
Resistance Level $21.39 $4.94
Average True Range (ATR) 0.90 0.15
MACD -0.08 -0.01
Stochastic Oscillator 51.00 65.31

Price Performance

Historical Comparison
FTRE
IVA

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: